Diagnosis: Glioblastoma multiforme.
Treatment: Xpovio.

The insurer denied Xpovio. The health plan's determination is overturned.

The patient is a male diagnosed with glioblastoma multiforme who is currently undergoing therapy with radiation and Temodar. Treatment with Xpovio is the subject of this review. The drug was denied by the plan as not medically necessary.

Xpovio is medically necessary.

The available evidence supports the use of Xpovio for treatment of glioblastoma. The available clinical evidence is from an open-label study, which showed that the drug demonstrated efficacy, with durable responses and disease stabilization in recurrent glioblastoma multiforme (GBM), and it was recommended for further development. In a phase II study for glioblastoma, the drug showed induced responses and also prolongation of progression free survival. As such, the use of this medication is a promising treatment strategy in addition to other first-line therapies, such as radiation and Temodar. The diagnosis of glioblastoma multiform has a dire prognosis, and nearly 95% of patients are dead at 5 years. This particularly therapy offers significant impacts in response and progression free survival on a difficult to treat cancer. It is medically necessary.